Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that CARGO Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy." The Company continued, "Based on an ad hoc analysis of FIRCE-1 prompted by recent safety events, the Company believes the results do not support a competitive benefit-risk profile of firi-cel for the intended patient population. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
In order to be eligible to join the CRGX class action lawsuit, you must have incurred a loss on shares of CARGO Therapeutics, Inc. purchased during the class period listed above.
TOP
